Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $109.09.
A number of research analysts have weighed in on BNTX shares. Evercore ISI started coverage on shares of BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price objective on the stock. BMO Capital Markets dropped their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $113.00 price objective on shares of BioNTech in a report on Monday, August 19th. HSBC raised BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a report on Wednesday, August 7th.
View Our Latest Analysis on BNTX
Institutional Investors Weigh In On BioNTech
BioNTech Stock Up 1.1 %
BNTX stock opened at $88.19 on Monday. The stock’s 50 day simple moving average is $83.88 and its 200 day simple moving average is $89.49. The company has a market cap of $20.97 billion, a P/E ratio of 176.38 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $125.83.
BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the prior year, the firm earned ($0.86) EPS. The company’s revenue was down 23.3% compared to the same quarter last year. On average, research analysts expect that BioNTech will post -2.04 earnings per share for the current fiscal year.
About BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Articles
- Five stocks we like better than BioNTech
- How to Calculate Return on Investment (ROI)
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- Investing in Commodities: What Are They? How to Invest in Them
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.